



(51) International Patent Classification:

C07C 215/70 (2006.01) **C07D 261/08** (2006.01)
C07C 311/00 (2006.01) **C07D 275/02** (2006.01)
C07C 317/00 (2006.01) **C07D 305/08** (2006.01)
C07C 233/00 (2006.01) **C07D 333/04** (2006.01)
C07D 213/71 (2006.01) **C07F 7/10** (2006.01)
C07D 231/18 (2006.01) **A61K 31/16** (2006.01)
C07D 233/84 (2006.01) **A61P 25/00** (2006.01)
C07D 249/12 (2006.01)

(21) International Application Number:

PCT/EP2010/051903

(22) International Filing Date:

16 February 2010 (16.02.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/152,825 16 February 2009 (16.02.2009) US

(71) Applicant (for all designated States except US): **ABBOTT GMBH & CO. KG** [DE/DE]; Max-Planck-Ring 2, 65205 Wiesbaden (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AMBERG, Wilhelm** [DE/DE]; c/o Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden (DE). **OCHSE, Michael** [DE/DE]; c/o Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden (DE). **LANGE, Udo** [DE/DE]; c/o Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden (DE). **KLING, Andreas** [DE/DE]; c/o Abbott GmbH & Co. KG, Max-Planck-Ring 2,

65205 Wiesbaden (DE). **BEHL, Berthold** [DE/DE]; c/o Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden (DE). **HORNBERGER, Wilfried** [DE/DE]; c/o Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden (DE). **MEZLER, Mario** [DE/DE]; c/o Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden (DE). **HUTCHINS, Charles** [US/US]; 31005 Prairie Ridge Rd., Green Oaks, Illinois 60048 (US).


(74) Agent: **Patentanwlte Reitsttter Kinzebach**; Sternwartstr. 4, 81679 Mnchen (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy



(57) Abstract: The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.



Published:

— *with international search report (Art. 21(3))*